Model of Streptococcus pneumoniae meningitis in adult rats
J G Strake1, M J Mitten, P J Ewing
1Department of Comparative Medicine, Abbott Laboratories, Abbott Park, Illinois, USA.
Abstract:
The purpose of this study was to develop a model of bacterial meningitis in young adult rats for assessing the efficacy of antimicrobial agents. Sixty 200- to 300-g male Sprague Dawley CD rats were inoculated intracisternally with 5.78 log10 CFU of a clinical isolate of Streptococcus pneumoniae in 5% hog gastric mucin. Inoculated rats were assigned to six groups containing 10 animals each. Group-1 rats served as controls and did not receive antibiotics. Rats of groups 2 to 4 received (subcutaneously every 12 h) cefotaxime (25, 6.25, and 1.56 mg/kg of body weight respectively). Rats of groups 5 and 6 received ampicillin (50 and 12.5 mg/kg respectively) and gentamicin (2.0 and 0.5 mg/kg respectively). Five additional Sprague Dawley CD rats were inoculated with only gastric hog mucin and were assigned to group 7. At postinoculation day 4 all animals were euthanized. Cerebral spinal fluid was collected for culturing. Brains were harvested for histologic examination and culturing. Untreated, infected control (group-1) animals were culture-positive for S. pneumoniae in the brain and cerebral spinal fluid. Of the antibiotic regimens evaluated, only cefotaxime (25 mg/kg) eradicated bacteria from the cerebral spinal fluid and brain. Cefotaxime at 25 or 6.25 mg/kg significantly (P < or = 0.05) decreased the bacterial burden of S. pneumoniae, whereas cefotaxime at 1.56 mg/kg and ampicillin/gentamicin combinations did not. There was histopathological evidence of subacute meningitis in infected rats. No meningitis was observed in rats receiving 25 mg of cefotaxime/kg. This model demonstrates the ability to induce bacterial meningitis with S. pneumoniae in adult rats and the ability to clear infection in 90 to 100% of the animals by administration of cefotaxime at dosages of 6.25 and 25 mg/kg given subcutaneously every 12 h.
Insights
This study developed a rat model for bacterial meningitis to test antibiotics. Cefotaxime effectively cleared Streptococcus pneumoniae meningitis in rats, showing promise for new treatments.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Bacterial meningitis remains a significant global health concern.
- Developing effective antimicrobial agents requires reliable preclinical models.
- Streptococcus pneumoniae is a leading cause of bacterial meningitis.
Purpose of the Study:
- To establish a reproducible rat model of bacterial meningitis.
- To evaluate the efficacy of cefotaxime and ampicillin/gentamicin in treating S. pneumoniae meningitis.
- To assess the impact of antibiotic treatment on bacterial load and histopathology.
Main Methods:
- Young adult Sprague Dawley rats were intracisternally inoculated with S. pneumoniae.
- Animals received various doses of cefotaxime or ampicillin/gentamicin.
- Cerebrospinal fluid and brain tissue were analyzed for bacterial presence and inflammation.
Main Results:
- The model successfully induced bacterial meningitis in untreated control rats.
- Cefotaxime at 25 mg/kg eradicated S. pneumoniae from the cerebrospinal fluid and brain.
- Cefotaxime (25 and 6.25 mg/kg) significantly reduced bacterial burden, while other treatments were ineffective.
- Histopathological examination revealed meningitis in infected rats, absent in those treated with high-dose cefotaxime.
Conclusions:
- A validated rat model for S. pneumoniae meningitis was developed.
- Cefotaxime demonstrates significant efficacy in clearing bacterial meningitis in this preclinical model.
- This model is suitable for assessing the therapeutic potential of antimicrobial agents against bacterial meningitis.
More Related Videos
10:03Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology
